Pharmacovigilance in Perspective

被引：0
|
作者：
Ronald H. B. Meyboom
Antoine C. G. Egberts
Frank W. J. Gribnau
Yechiel A. Hekster
机构：
[1] Netherlands Pharmacovigilance Foundation LAREB,Department of Pharmacoepidemiology and Pharmacotherapy
[2] Utrecht University,Department of Clinical Pharmacology
[3] TweeSteden Ziekenhuis,Department of Clinical Pharmacy
[4] Nijmegen University Hospital St Radboud,undefined
[5] Nijmegen University Hospital St Radboud,undefined
[6] The Uppsala Monitoring Centre,undefined
来源：
Drug Safety | 1999年 / 21卷
关键词：
Adis International Limited; Adverse Drug Reaction; Spontaneous Reporting; Drug Regulation; Pharmacovigilance Centre;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Pharmacovigilance is more than spontaneous reporting alone, and the evaluation of marketed medicines is more than just pharmacovigilance. The positioning of a drug usually takes place during the years following introduction, when worldwide experience has accumulated. Originally a modest appendix of drug regulation, pharmacovigilance has become a major activity. The provision of the information needed for the evaluation of the benefits and risks of drugs is in the first place a scientific challenge. In addition, there are important ethical, logistical, legal, financial and commercial constraints. Good pharmacovigilance practice needs to be developed to ensure that data are collected and used in the right way and for the right purpose.
引用
收藏
页码：429 / 447
页数：18
相关论文
共 50 条
  • [21] Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance
    Raymond Kassekert
    Neal Grabowski
    Denny Lorenz
    Claudia Schaffer
    Dieter Kempf
    Promit Roy
    Oeystein Kjoersvik
    Griselda Saldana
    Sarah ElShal
    [J]. Drug Safety, 2022, 45 : 439 - 448
  • [22] Hepatic Models in Precision Medicine: An African Perspective on Pharmacovigilance
    Hurrell, Tracey
    Naidoo, Jerolen
    Scholefield, Janine
    [J]. FRONTIERS IN GENETICS, 2022, 13
  • [23] Vaccine pharmacovigilance in India: Current context and future perspective
    Meher, Bikash Ranjan
    [J]. INDIAN JOURNAL OF PHARMACOLOGY, 2019, 51 (04) : 243 - 247
  • [24] The Qualified Person for Pharmacovigilance for EuropeA Compliance and Quality Perspective
    Elliot G. Brown
    [J]. International Journal of Pharmaceutical Medicine, 2005, 19 (1) : 7 - 14
  • [25] Issues with pharmacovigilance in Eastern Europe countries: The industry perspective
    Dujmovic, Ivana Hanzl
    Sernhorst, Ivana Staresinic
    [J]. TOXICOLOGY LETTERS, 2006, 164 : S27 - S28
  • [26] How could employing the patient perspective transform pharmacovigilance?
    van den Bemt, P. M. L. A.
    van Puijenbroek, E. P.
    van Hunsel, F. P. A. M.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (07) : 793 - 796
  • [27] The Qualified Person for Pharmacovigilance for Europe A Compliance and Quality Perspective
    Brown, Elliot G.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL MEDICINE, 2005, 19 (01): : 7 - 14
  • [28] Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance
    Kassekert, Raymond
    Grabowski, Neal
    Lorenz, Denny
    Schaffer, Claudia
    Kempf, Dieter
    Roy, Promit
    Kjoersvik, Oeystein
    Saldana, Griselda
    ElShal, Sarah
    [J]. DRUG SAFETY, 2022, 45 (05) : 439 - 448
  • [29] Pharmacovigilance in veterinary medicine:: an international perspective and the current situation in Chile
    Iragueen, D.
    Urcelay, S.
    Martina, B. San
    [J]. ARCHIVOS DE MEDICINA VETERINARIA, 2007, 39 (03) : 195 - 206
  • [30] Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective
    Baptista, Alexandre
    Macedo, Ana M.
    Marreiros, Ana
    Coelho, Andre
    Perazella, Mark A.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
12345